Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Legend Biotech ( (LEGN) ) just unveiled an announcement.
Legend Biotech announced the appointment of Carlos Santos as Chief Financial Officer on August 18, 2025. Santos, who brings extensive experience from AstraZeneca and other major firms, will oversee financial operations to support the company’s strategic goals, including achieving profitability by 2026. His appointment is expected to strengthen Legend Biotech’s financial discipline and support the continued success of its CAR-T cell therapy franchise, CARVYKTI®.
The most recent analyst rating on (LEGN) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
Spark’s Take on LEGN Stock
According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.
Legend Biotech’s overall score is driven by strong earnings call highlights, including significant sales growth and strategic advancements. However, financial performance and valuation concerns, such as ongoing losses and negative cash flows, weigh down the score. Technical indicators suggest potential oversold conditions, but bearish momentum persists.
To see Spark’s full report on LEGN stock, click here.
More about Legend Biotech
Legend Biotech is a global leader in cell therapy, focusing on innovative treatments for cancer. The company is renowned for its CAR-T cell therapy, CARVYKTI®, which is developed in collaboration with Johnson & Johnson. With a workforce of over 2,800 employees, Legend Biotech is committed to expanding patient access and therapeutic potential of CARVYKTI® while driving future innovations in cell therapy.
Average Trading Volume: 1,621,205
Technical Sentiment Signal: Hold
Current Market Cap: $6.92B
For an in-depth examination of LEGN stock, go to TipRanks’ Overview page.